01—Abstract
Summary
Summary of the 10-K filed February 28, 2014. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation's (EW) 2013 10-K filing highlights robust growth, particularly in its Transcatheter Heart Valve (THV) segment, which saw sales increase by 28.2%a year-over-year, driven by strong performance in both the US and international markets.
This growth in THV, coupled with modest increases in Surgical Heart Valve Therapy, helped offset a slight decline in Critical Care sales. The company's overall net sales increased by 7.7% to $2.05 billionb. Financially, EW demonstrated improved profitability, with diluted EPS growing by 38.7% to $3.44.
This was bolstered by a favorable product mix, increased sales volume, and a significant one-time gain of $52.3 millionc (net of tax) from a litigation award against Medtronic. The company continues to invest heavily in research and development, with R&D expenses rising to 15.8% of net sales, underscoring its commitment to innovation in structural heart disease and critical care monitoring.
Looking ahead, EW faces increasing competition in the transcatheter valve market but is well-positioned due to its established leadership and ongoing development of next-generation products like the SAPIEN 3 valve. The company's financial position remains strong, supported by healthy operating cash flow and a significant share repurchase program.
02—Key points
Key Highlights
- Net sales grew 7.7% to $2.05 billion in 2013, driven by strong performance in Transcatheter Heart Valves (+28.2%).
- Transcatheter Heart Valves now represent 35% of total net sales, up from 20% in 2011, indicating a significant shift in product mix.
- Diluted EPS increased by 38.7% to $3.44, reflecting improved operational performance and a significant litigation award.
- Research and Development (R&D) spending increased by 10.9% to $323.0 million, representing 15.8% of net sales, highlighting a focus on innovation.
- The company received FDA approval for the SAPIEN 3 valve in Europe in January 2014 and initiated US studies, signaling continued investment in next-generation transcatheter technologies.
- A significant litigation award of $83.6 million from Medtronic was received in February 2013, positively impacting net income.
- The company repurchased $495.1 million of its common stock in 2013, demonstrating a commitment to returning capital to shareholders.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2013filed February 28, 2014Financial Statements
FY2013 against FY2012
| Line item | FY2013FY2012 | Change |
|---|---|---|
| Revenue | $2.05B$1.90B | +7.7% |
| Cost of Revenue | $516.60M$491.00M | +5.2% |
| Gross Profit | $1.53B$1.41B | +8.5% |
| R&D Expenses | $323.00M$291.30M | +10.9% |
| SG&A Expenses | $733.40M$697.40M | +5.2% |
| Interest Expense | $9.80M$4.40M | +122.7% |
| Net Income | $389.10M$291.50M | +33.5% |
| EPS (Basic) | $0.58$0.42 | +37.0% |
| EPS (Diluted) | $0.57$0.41 | +39.0% |
| Shares Outstanding (Basic) | 670.20M689.40M | −2.8% |
| Shares Outstanding (Diluted) | 682.80M709.80M | −3.8% |
05—Questions
Frequently Asked Questions
What are Edwards Lifesciences' primary business segments and their performance in 2013?
Edwards Lifesciences operates in three main segments: Surgical Heart Valve Therapy, Transcatheter Heart Valves (THV), and Critical Care. In 2013, THV showed the strongest growth, with sales increasing by 28.2% to $707.7 million. Surgical Heart Valve Therapy sales grew modestly by 1.7% to $801.2 million. Critical Care sales decreased by 4.2% to $536.6 million.
How did the company's financial performance evolve in 2013 compared to 2012?
In 2013, Edwards Lifesciences reported a 7.7% increase in net sales to $2.05 billion, compared to $1.90 billion in 2012. Net income rose significantly by 33.6% to $391.7 million, with diluted earnings per share growing by 38.7% to $3.44. This performance was boosted by strong THV sales and a $52.3 million net litigation award.
What is the company's strategy regarding research and development (R&D) and new product introductions?
Edwards Lifesciences continues to prioritize R&D, investing $323.0 million in 2013, representing 15.8% of net sales. A significant portion of this investment is directed towards developing next-generation transcatheter heart valve technologies, including the SAPIEN 3 valve, and enhancing its surgical heart valve and critical care portfolios. The company aims to maintain its leadership in structural heart disease and critical care monitoring through these innovation efforts.
What are the main risks facing Edwards Lifesciences as highlighted in the 10-K?
Key risks include intense competition, particularly in the transcatheter heart valve market, the need for timely new product introductions to avoid obsolescence, potential product liability claims, reliance on a complex supply chain, and the impact of government regulation and healthcare cost containment measures. The company also faces risks associated with international operations and currency fluctuations.
06—Continue